Fig. 2.

Cumulative incidence curves of three competing risk events during first-line chemotherapy. a AE-ILD, (b) PD of lung cancer and (c) other events without AE-ILD. There was a significant difference in occurrence of AE-ILD between the Bev (dotted line) and non-Bev (solid line) groups (p = 0.037, Gray’s test). AE-ILD, acute exacerbation of interstitial lung disease; PD, progressive disease